Gout drug could cut length of hospitalisation in patients with moderate to severe COVID-19



A trial investigating the gout drug colchicine as a treatment for COVID-19 has suggested it reduces the length of both supplemental oxygen therapy and hospitalisation in patients with moderate to severe COVID-19.



Source link

Share and Enjoy !

0Shares
0 0
Close